Ex­clu­sive: No­vo foun­da­tion's growth arm is mak­ing an in­vest­ment push in­to health­care, ex­pand­ing be­yond life sci­ences

(This sto­ry is from our new Health Tech newslet­ter. If you’d like to sign up, just click here.) 

No­vo Hold­ings, the in­vest­ment arm of No­vo Nordisk’s par­ent foun­da­tion, is mak­ing a push in­to health­care through its growth in­vest­ing arm, with a fo­cus on mak­ing sig­nif­i­cant bets on med­ical tech­nol­o­gy and health­care ser­vices com­pa­nies.

The foun­da­tion’s as­sets have swollen thanks to the block­buster suc­cess of drug­mak­er No­vo Nordisk’s GLP-1 prod­ucts for weight loss and di­a­betes. No­vo Hold­ings man­ages the as­sets of the foun­da­tion, which has stakes in the phar­ma­ceu­ti­cal gi­ant No­vo Nordisk as well as Novozymes. It al­so in­vests in life sci­ences com­pa­nies and oth­ers with the aim of gen­er­at­ing re­turns for the foun­da­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER